Measurement of MxA mRNA or protein as a biomarker of IFNβ bioactivity -: Detection of antibody-mediated decreased bioactivity (ADB)

被引：63

作者：

Pachner, AR

Bertolotto, A

Deisenhammer, F

机构：

[1] UMDNJ New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ 07102 USA

[2] CreSM & Neurol Clin, Orbassano, TO, Italy

[3] Univ Innsbruck, A-6020 Innsbruck, Austria

来源：

NEUROLOGY | 2003年 / 61卷 / 09期

关键词：

D O I：

10.1212/01.WNL.0000092361.04511.D0

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Myxovirus A (MxA) is a protein that is specifically induced by treatment with type I cytokines and has proven to be a reliable biomarker of interferon-beta (IFNbeta) bioactivity. IFNbeta-induced MxA can be measured as either protein or mRNA in the blood of IFNbeta-treated patients with MS. In patients with MS who are treated with IFNbeta, loss of the MxA response is caused by high levels of anti-IFNbeta antibodies and is a sensitive marker of lost bioactivity.

引用

收藏

页码：S24 / S26

页数：3

相关论文

共 16 条

[1] Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients [J].

Bertolotto, A ;

Gilli, F ;

Sala, A ;

Capobianco, M ;

Malucchi, S ;

Milano, E ;

Melis, F ;

Marnetto, F ;

Lindberg, RLP ;

Bottero, R ;

Di Sapio, A ;

Giordana, MT .

NEUROLOGY, 2003, 60 (04) :634-639

[2] Evaluation of bioavailability of three types of IFNβ in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification [J].

Bertolotto, A ;

Gilli, F ;

Sala, A ;

Audano, L ;

Castello, A ;

Magliola, U ;

Melis, F ;

Giordana, MT .

JOURNAL OF IMMUNOLOGICAL METHODS, 2001, 256 (1-2) :141-152

[3] The MxA protein levels in whole blood lysates of patients with various viral infections [J].

Chieux, V ;

Hober, D ;

Harvey, J ;

Lion, G ;

Lucidarme, D ;

Forzy, G ;

Duhamel, M ;

Cousin, J ;

Ducoulombier, H ;

Wattré, P .

JOURNAL OF VIROLOGICAL METHODS, 1998, 70 (02) :183-191

[4] Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies [J].

Deisenhammer, F ;

Reindl, M ;

Harvey, J ;

Gasse, T ;

Dilitz, E ;

Berger, T .

NEUROLOGY, 1999, 52 (06) :1239-1243

[5] A comparative study of the relative bioavailability of different interferon beta preparations [J].

Deisenhammer, F ;

Mayringer, I ;

Harvey, J ;

Dilitz, E ;

Gasse, T ;

Stadlbauer, D ;

Reindl, M ;

Berger, T .

NEUROLOGY, 2000, 54 (11) :2055-2060

[6] INTERFERONS, MX-GENES, AND RESISTANCE TO INFLUENZA-VIRUS [J].

HORISBERGER, MA .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 152 (04) :S67-S71

[7] AN ANALYSIS OF NEUTRALIZATION REACTION OF INTERFERON BY ANTIBODY - A PROPOSAL ON THE EXPRESSION OF NEUTRALIZATION TITER [J].

KAWADE, Y .

JOURNAL OF INTERFERON RESEARCH, 1980, 1 (01) :61-70

[8] A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta [J].

Kob, M ;

Harvey, J ;

Schautzer, F ;

Kascha, S ;

Bibl, D ;

Egg, R ;

Reindl, M ;

Berger, T ;

Deisenhammer, F .

MULTIPLE SCLEROSIS JOURNAL, 2003, 9 (01) :32-35

[9] Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS [J].

Kracke, A ;

von Wussow, P ;

Al-Masri, AN ;

Dalley, G ;

Windhagen, A ;

Heidenreich, F .

NEUROLOGY, 2000, 54 (01) :193-199

[10]

Pachner Andrew, 2003, Mol Diagn, V7, P17, DOI 10.2165/00066982-200307010-00004